Plain-English translation of NCT06651853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for people with diffuse large B-cell lymphoma that has either come back after treatment or did not respond to initial therapy. The study combines radiation therapy with three medications: lenalidomide, glofitamab (a monoclonal antibody that targets cancer cells), and a growth factor called GM-CSF. The goal is to see if this combination can help people whose cancer has proven difficult to treat.
Standard treatments don't work for all lymphoma patients—some experience relapse or never respond to initial therapy in the first place. This medication and this combination approach represent a newer strategy that may help people who have limited options remaining.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy combined with three medications over multiple treatment cycles. The exact schedule of visits and treatment duration would be determined by your doctors, but you would be closely monitored with blood tests and imaging scans to track how well the treatment is working and to watch for any side effects. Because this is a phase 2 trial, the research team is learning about both how effective this combination is and what side effects to expect.
AI-generated summary from trial data · Aug 23, 2026 · Not medical advice
China